Profile data is unavailable for this security.
About the company
Vineet Laboratories Limited is engaged in the business of drug intermediates and bulk drugs. The Company specializes in pharmaceutical intermediates and fine chemicals. Its active pharmaceutical ingredient (API) intermediates include Lopinavir, Ritonavir, Efavirenz, Nadolol, Glimepiride, Celecoxib, and Piroctone Olanine. Its fine chemicals and reagents include Isopropyl-beta-D-thiogalactopyranoside, 4-Nitrophenyl phosphate disodium salt, 5-Bromo-4-chloro-3-indolyl-beta-D-galactopyranoside (X-Gal), 5-Acetyl thiophene-2-carboxilic acid, n-Butyl Lithium, n-Butyl magnesium chloride, 3-Furaldehyde, 3-bromofuran, 1-methyl-imidazole-2-carboxaldehyde, 6-Aminouracil, Ethyldiazo acetate, and Phenylboronic acid. It also exports API intermediates, fine chemicals, and custom synthesis molecules.
- Revenue in INR (TTM)1.37bn
- Net income in INR1.46m
- Incorporated2016
- Employees--
- LocationVineet Laboratories LtdHYDERABAD 500074IndiaIND
- Phone+91 4 024128833
- Websitehttp://vineetlabs.co.in/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jupiter Bioscience Ltd | -100.00bn | -100.00bn | 369.03m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.42 | -- | 5.61 | -- | 61.37 | -- | 17.32 | -- | -- | -- | 10.48 | 42.43 | 29.30 | 20.92 | 22.82 | 55.40 | -16.74 |
Vivimed Labs Ltd | 1.47bn | -3.17bn | 410.42m | 607.00 | -- | -- | -- | 0.2783 | -38.77 | -38.77 | 17.88 | -- | -- | -- | -- | 2,429,737.00 | -- | -5.92 | -- | -8.97 | -62.46 | 33.74 | -214.73 | -14.20 | -- | -6.31 | -- | -- | -21.15 | -30.83 | -385.64 | -- | -- | -- |
Vineet Laboratories Ltd | 1.37bn | 1.46m | 545.21m | -- | 338.06 | 1.67 | 20.45 | 0.3982 | 0.1749 | 0.1749 | 148.76 | 35.35 | -- | -- | -- | -- | -- | -- | -- | -- | 25.44 | -- | 0.107 | -- | 0.4833 | 0.7313 | 0.565 | -- | -29.06 | -- | -18.00 | -- | -- | -- |
Mono Pharmacare Ltd | -100.00bn | -100.00bn | 617.52m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 58.12 | -- | 251.10 | -- | -- | -- |
JFL Life Sciences Ltd | -100.00bn | -100.00bn | 725.90m | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 8.63 | -- | 50.42 | -- | -- | -- |